Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

• Status: Completed
• Trial end date: 2015-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for polypoidal choroidal vasculopathy (PCV) and find the optimal treatment for PCV.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Ranibizumab; Verteporfin

Criteria

Inclusion Criteria:

1. active macula-involved polypoidal lesions evidenced by ICGA;

2. greatest linear dimension of 5400 μm or less assessed by ICGA;

3. follow-up of at least 12 months.

Exclusion Criteria:

1. any other ocular disease, such as ocular trauma, glaucoma, uveitis, diabetic retinopathy, angioid streaks, pathologic myopia, or presumed ocular histoplasmosis syndrome;

2. any systemic contraindication to the PDT, IVR, sodium fluorescein, or indocyanine green dyes;

3. any severe uncontrolled systemic disease, such as uncontrolled hypertention, coronary heart disease, liver failure, or kidney failure.